ABVX
Abivax·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Consensus Rating "Buy"
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABVX
Abivax Sa
A biotechnology company focused on harnessing the body's natural regulatory mechanisms to modulate the clinical stages of chronic inflammatory diseases
Biological Technology
12/04/2013
10/20/2023
NASDAQ Stock Exchange
69
12-31
Depository Receipts (Ordinary Shares)
7-11 boulevard Haussmann, 75009 Paris, France
--
Abivax Sa was incorporated on December 4, 2013 under the laws of France. The company is a clinical-stage biotechnology company focused on developing therapies that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is currently evaluating the lead drug candidate, Oberfazmod, in a Phase 3 clinical trial for the treatment of moderate-to-severe active ulcerative colitis in adults.
Company Financials
Revenue & Expenses
ABVX has released its 2025 Q2 earnings report, with revenue of 1.29M, reflecting a YoY change of -78.66%, and net profit of -56.98M, showing a YoY change of -37.22%. The Sankey diagram below clearly presents ABVX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
